FR2368282B1 - - Google Patents

Info

Publication number
FR2368282B1
FR2368282B1 FR7631935A FR7631935A FR2368282B1 FR 2368282 B1 FR2368282 B1 FR 2368282B1 FR 7631935 A FR7631935 A FR 7631935A FR 7631935 A FR7631935 A FR 7631935A FR 2368282 B1 FR2368282 B1 FR 2368282B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7631935A
Other languages
French (fr)
Other versions
FR2368282A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bpifrance Financement SA
Original Assignee
Agence National de Valorisation de la Recherche ANVAR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agence National de Valorisation de la Recherche ANVAR filed Critical Agence National de Valorisation de la Recherche ANVAR
Priority to FR7631935A priority Critical patent/FR2368282A1/fr
Priority to CH1280977A priority patent/CH626629A5/fr
Priority to GB43832/77A priority patent/GB1590659A/en
Priority to DE19772747379 priority patent/DE2747379A1/de
Priority to JP12588277A priority patent/JPS5353628A/ja
Priority to US05/845,105 priority patent/US4185089A/en
Publication of FR2368282A1 publication Critical patent/FR2368282A1/fr
Application granted granted Critical
Publication of FR2368282B1 publication Critical patent/FR2368282B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
FR7631935A 1976-10-22 1976-10-22 Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine Granted FR2368282A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR7631935A FR2368282A1 (fr) 1976-10-22 1976-10-22 Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine
CH1280977A CH626629A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1976-10-22 1977-10-20
GB43832/77A GB1590659A (en) 1976-10-22 1977-10-21 Immunological adjuvant constituted by the p-aminophenyl derivative of n-acetylmuramyl-l-alanyl-d-isoglutamine
DE19772747379 DE2747379A1 (de) 1976-10-22 1977-10-21 P-amino-phenyl-n-acetyl-muramyl-l- alanyl-d-isoglutamin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel
JP12588277A JPS5353628A (en) 1976-10-22 1977-10-21 Nnacetyllmuramyllllalanylldd isogultamine ppaminophenyl derivatives* and immunological adjant containing said compound and process for preparation thereof
US05/845,105 US4185089A (en) 1976-10-22 1977-10-25 Immunological adjuvant constituted by the p-amino-phenyl derivative of N-acetyl-muramyl-L-alanyl-D-isoglutamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7631935A FR2368282A1 (fr) 1976-10-22 1976-10-22 Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine

Publications (2)

Publication Number Publication Date
FR2368282A1 FR2368282A1 (fr) 1978-05-19
FR2368282B1 true FR2368282B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1980-10-17

Family

ID=9179110

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7631935A Granted FR2368282A1 (fr) 1976-10-22 1976-10-22 Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine

Country Status (6)

Country Link
US (1) US4185089A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5353628A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH626629A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2747379A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2368282A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1590659A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2428051A1 (fr) * 1978-06-05 1980-01-04 Anvar Nouveaux composes du type muramyl-peptide et medicaments les contenant
US4377570A (en) * 1979-01-29 1983-03-22 Merck & Co., Inc. Immunologically active dipeptidyl saccharides and methods of preparation
FR2449697A1 (fr) 1979-02-20 1980-09-19 Anvar Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant
FI75578C (fi) * 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US5416070A (en) * 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
RU2083588C1 (ru) * 1995-09-11 1997-07-10 Безруков Михаил Васильевич Способ получения мурамилпептидов
AUPR079700A0 (en) 2000-10-17 2000-11-09 Alchemia Pty Ltd Combinatorial libraries of monosaccharides
WO2005013918A2 (en) 2003-02-28 2005-02-17 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to poxvirus subunit vaccines
EP1781338A4 (en) * 2004-07-19 2010-02-10 Baylor College Medicine MODULATION OF CYTOKIN SIGNALING REGULATORS AND APPLICATIONS FOR IMMUNOTHERAPY
JP2008542405A (ja) * 2005-06-08 2008-11-27 ニューバイオメッド ピーアイケイエイ プライベート リミテッド ポリイノシン酸‐ポリシチジル酸に基づくアジュバント
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
US20070166239A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
WO2008116347A1 (en) 2007-03-26 2008-10-02 General Regeneratives Limited Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
US8324369B2 (en) * 2007-11-30 2012-12-04 Baylor College Of Medicine Dendritic cell vaccine compositions and uses of same
WO2011038002A1 (en) 2009-09-22 2011-03-31 Yale University Immunogenic epitopes as targets for universal cancer vaccines
US9446112B2 (en) 2011-07-12 2016-09-20 Philadelphia Health & Education Corporation Clostridium difficile DNA vaccine
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
RU2678981C2 (ru) 2014-12-23 2019-02-05 Йишенг Байофарма (Сингапур) Пте Лтд Композиция от бешенства, содержащая адъювант pika
WO2016138286A1 (en) 2015-02-26 2016-09-01 Stc.Unm Irgm and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
WO2020140007A1 (en) 2018-12-28 2020-07-02 University Of Rochester Gene therapy for best1 dominant mutations
WO2025096754A1 (en) 2023-10-31 2025-05-08 Musc Foundation For Research Development The use of enolase inhibitor pomhex for treatment of fibrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082735A (en) * 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof
US4082736A (en) * 1976-04-26 1978-04-04 Syntex (U.S.A.) Inc. Novel immunological adjuvant compounds and methods of preparation thereof

Also Published As

Publication number Publication date
FR2368282A1 (fr) 1978-05-19
JPS6126800B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-06-21
JPS5353628A (en) 1978-05-16
US4185089A (en) 1980-01-22
GB1590659A (en) 1981-06-03
DE2747379A1 (de) 1978-04-27
CH626629A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-11-30

Similar Documents

Publication Publication Date Title
FR2368282B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2370295B3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR7700741A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5613212Y2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5333355U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5317334U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5387969U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5522115Y2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5543697B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS175504B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5350840U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS178348B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS178350B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5389156U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS178363B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5320717U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS178381B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5317578U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS178499B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS178372B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG23295A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH597989A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD124164A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD123973A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD124284A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Legal Events

Date Code Title Description
ST Notification of lapse